Evidence map›Paper›PMID 39758667›Full record

ArticleACS omega2024

Yttrium-Enriched Phosphate Glass-Ceramic Microspheres for Bone Cancer Radiotherapy Treatment.

Ben Milborne, Andi Arjuna, Md Towhidul Islam, Abul Arafat, Robert Layfield, Alexander Thompson, Ifty Ahmed

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ben MilborneAdvanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID https://orcid.org/0000-0003-4744-3354
Andi ArjunaAdvanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, U.K.
Md Towhidul IslamAdvanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, U.K.
Abul ArafatSchool of Engineering, University of Wolverhampton, Telford Innovation Campus, Telford TF2 9NT, U.K.
Robert LayfieldSchool of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.ORCID https://orcid.org/0000-0003-0702-3259
Alexander ThompsonBiodiscovery Institute, Division of Cancer and Stem Cells, University of Nottingham, Nottingham NG7 2RD, U.K.
Ifty AhmedAdvanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID https://orcid.org/0000-0001-7868-3698

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents the development and characterization of high yttrium-content phosphate-based glass-ceramic microspheres for potential applications in bone cancer radiotherapy treatment. The microspheres produced via flame spheroidization, followed by sieving, revealed a lack of aggregation and a narrow size distribution (45-125 μm) achieved across different yttrium oxide to glass ratio samples. Energy dispersive X-ray (EDX) analysis showed a significant increase in yttrium content within the microspheres with increasing yttrium oxide to glass ratio samples, ranging from approximately 1-39 mol % for 10Y-50Y microspheres, respectively. Concurrently, a proportional decrease in the phosphate, calcium, and magnesium content was observed. Further EDX mapping showed a homogeneous distribution of all elements throughout the microspheres, indicating uniform composition. X-ray diffraction profiles confirmed the amorphous nature of the starting P40 glass microspheres, while yttrium-containing microspheres exhibited crystalline peaks corresponding to cubic and hexagonal Y

Identifiers

PMID39758667
PMCPMC11696403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.